REGENXBIO Inc. (NASDAQ:RGNX) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET
Company Participants
Patrick Christmas - Chief Legal Officer
Ken Mills - President and CEO
Steve Pakola - Chief Medical Officer
Vit Vasista - CFO
Conference Call Participants
Andreas Argyrides - Wedbush Securities
Operator
Good day and thank you for standing by. Welcome to the Q1 2022 REGENXBIO Inc. Earnings Conference Call. At this time, all participants are in listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions]
I would now like to hand the conference over to our speaker today Mr. Patrick Christmas, Chief Legal Officer. Please go ahead.
Patrick Christmas
Good afternoon and thank you for joining us today. With us are Ken Mills, REGENXBIO’s President and Chief Executive Officer; Dr. Steve Pakola, our Chief Medical Officer; and Vit Vasista, our Chief Financial Officer. Earlier this afternoon, REGENXBIO released financial and operating results for the first quarter ended March 31, 2022. The press release reporting our financial results is available on our website at www.regenxbio.com.
Today’s conference call will include forward-looking statements regarding our financial outlook in addition to regulatory and product development plans. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted and can be identified by words such as expect, plan, will, may, anticipate, believe, should, intend and other words of similar meaning. Any such forward-looking statements are not guarantees of future performance and involve certain risks and uncertainties.
These risks are described in the Risk Factors and the management’s discussion and analysis sections of REGENXBIO’s annual report on Form 10-K for the full year ended December 31, 2021, and Comparable Risk Factors sections of REGENXBIO’s quarterly reports on Form 10-Q which are on file with the Securities and Exchange Commission and available on the SEC’s website. Any information we provide on this conference call is provided only as of the date of this call, May 4, 2022, and we undertake no obligation to update any forward-looking statements we may make on this call on account of new information, future events or otherwise.
Please be advised that today’s call is being recorded and webcast. In addition, any unaudited or pro forma financial information that may be provided is preliminary and does not purport to project financial positions or operating results of the company. Actual results may differ materially.